Correspondence 0001104659-24-101741 from Theriva Biologics, Inc. (TOVX)
Theriva Biologics, Inc.
Date: Sept. 20, 2024 · CIK: 0000894158 · Accession: 0001104659-24-101741
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282024
Letter
VIA EDGAR United States Securities Division of Corporation Finance Attention: Jessica Dickerson Re: Theriva Biologics, Inc. Registration Statement on Form S-1 Filed September 10, 2024 File No: 333-282024
Dear Ms. Dickerson:
Theriva Biologics, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-282024), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to become effective on Monday, September 23, 2024, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes Leslie Marlow of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 457-4238 with any questions you may have concerning this request, and please notify her when this request for acceleration has been granted.
Very truly yours,
THERIVA BIOLOGICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
September 20, 2024
VIA EDGAR
United States Securities
and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jessica Dickerson
Re:
Theriva Biologics, Inc.
Registration Statement on Form S-1
Filed September 10, 2024
File No: 333-282024
Dear Ms. Dickerson:
Theriva Biologics, Inc. (the
“Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-1 (File
No. 333-282024), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to become effective
on Monday, September 23, 2024, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands
that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities
under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes
Leslie Marlow of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 457-4238
with any questions you may have concerning this request, and please notify her when this request for acceleration has been granted.
Very truly yours,
THERIVA BIOLOGICS, INC.
By:
/s/ Steven A. Shallcross
Name:
Steven A. Shallcross
Title:
Chief Executive Officer and Chief Financial Officer
cc: Leslie Marlow, Blank Rome LLP